Core D: Protein Production Core
核心 D:蛋白质生产核心
基本信息
- 批准号:7777115
- 负责人:
- 金额:$ 35.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:Affinity ChromatographyAgonistAntibody AffinityBiochemicalBioreactorsBrainCell LineCore FacilityDevelopmentEpitopesEquilibriumGated Ion ChannelGeneral anesthetic drugsGoalsHumanInstructionLaboratoriesLeadLigandsLipid BilayersMammalian CellMinorMissionMutationNeuronsPharmacologyPositioning AttributeProductionProteinsResearch PersonnelResourcesServicesSiteSynaptic ReceptorsTechniquesTerminologyTetanus Helper PeptideTimebasedesigndesign and constructionexperiencemembermilligrammutantprogramsreceptorreconstitutionstable cell line
项目摘要
The Protein Production Core's mission is to produce heterologously expressed, purified and reconstituted
human neuronal receptors in the large quantities required for photolabeling and sequencing. This is a
challenging resource-intensive objective best handled by a central facility. During the four years of its
existence, the Core has thoroughly developed several inducible mammalian cell lines capable of expressing
a number of Cys-loop ligand-gated ion channel receptors bearing accessible purification epitopes. With such
cell lines the successive steps of solubilization, purification and reconstitution have been optimized. Two
receptors are now in production in such cell lines, and it is proposed to developed three more. Using its
Bioreactor facility, the Core is now in a position to routinely fulfill its overall specific aim of supplying Projects
1 & 2 with the milligram quantities of well characterized, purified receptors functionally reconstituted into
defined lipid bilayers that are required for photolabeling studies. The specific receptors to be produced in this
way are all human neuronal members of the Cys-loop superfamily. The primary focus is on the inhibitory
receptors, specifically the following GABAA receptors: synaptic receptors composed of subunits aip3y2L:
extrasynaptic receptors composed of subunits a4p36, and aipS receptors to act as controls. The
representative excitatory receptors in the Cys-loop superfamily will be the neuronal nicotinic a4p2 receptor
and the 5-HT3A receptor. A subsidiary goal is to support the needs of investigators involved in
electrophysiological studies (Raines and Forman). They will be able to achieve efficiencies by using the
Core's resources both for the more straightfonward establishment of stable cell lines and for the development
of mutants, although the primary responsibility remains with the investigator thereafter. This latter service will
not detract from the Core's main labor-intensive goal of developing stable, inducible cell lines and over-
expressing human neuronal receptors for photolabeling and biochemical studies. The Core will be situated in
the Mallinckrodt Pharmacology Laboratory at MGH.
RELEVANCE (See instructions):
蛋白质生产核心的使命是生产异源表达,纯化和重组
人神经元受体的大量光标记和测序所需的。这是一
具有挑战性的资源密集型目标最好由中央设施来处理。在其四年的
存在,核心已经彻底开发了几种诱导型哺乳动物细胞系能够表达
许多携带可接近纯化表位的Cys环配体门控离子通道受体。与这些
细胞系已经优化了溶解、纯化和重构的连续步骤。两
现在,在这些细胞系中已经开始生产受体,并建议再开发三种受体。使用其
生物反应器设施,核心现在能够定期实现其总体特定目标,
图1和2中所示的受体与毫克量的充分表征的、纯化的受体在功能上重构为
定义的脂质双层,这是光标记研究所需的。这种细胞中产生的特异性受体
所有的人都是Cys环超家族的神经元成员。主要关注的是抑制性
受体,特别是以下GABAA受体:由亚基aip 3 γ 2L组成的突触受体:
由亚基a4 p36组成的突触外受体和aipS受体作为对照。的
Cys环超家族中的代表性兴奋性受体是神经元烟碱α 4 β 2受体
和5-HT 3A受体。一个次要的目标是支持调查人员的需要,
电生理学研究(Raines和Forman)。他们将能够通过使用
核心的资源,既为更直接地建立稳定的细胞系,并为发展
突变体,虽然主要责任仍然是由研究人员之后。后一项服务将
不减损核心的主要劳动密集型目标,即开发稳定的、可诱导的细胞系,
表达人神经元受体用于光标记和生物化学研究。核心将位于
麻省总医院的马林克罗特药理学实验室
相关性(参见说明):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEITH W MILLER其他文献
KEITH W MILLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEITH W MILLER', 18)}}的其他基金
Molecular Pharmacology of the Synaptic and Extrasynaptic GABA(A) Receptors
突触和突触外 GABA(A) 受体的分子药理学
- 批准号:
10557233 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Molecular Pharmacology of the Synaptic and Extrasynaptic GABA(A) Receptors
突触和突触外 GABA(A) 受体的分子药理学
- 批准号:
10356109 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
General Anesthetic Sites on Ligand-Gated Ion Channels
配体门控离子通道上的全身麻醉位点
- 批准号:
8074636 - 财政年份:2010
- 资助金额:
$ 35.64万 - 项目类别:
Project 2: Action of general anesthetics on transient states of ligand-gated ion
项目2:全身麻醉剂对配体门控离子瞬态的作用
- 批准号:
7777110 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
STRUCTURAL STUDIES OF ANESTHETIC BINDING SITE IN PROTEIN KINASE C (PKC)
蛋白激酶 C (PKC) 中麻醉剂结合位点的结构研究
- 批准号:
7721211 - 财政年份:2008
- 资助金额:
$ 35.64万 - 项目类别:
STRUCTURAL STUDIES OF ANESTHETIC BINDING SITE IN PROTEIN KINASE C (PKC)
蛋白激酶 C (PKC) 中麻醉剂结合位点的结构研究
- 批准号:
7369502 - 财政年份:2005
- 资助金额:
$ 35.64万 - 项目类别:
General Anesthetic-Protein Interactions:Protein Kinase C
全身麻醉药-蛋白质相互作用:蛋白激酶 C
- 批准号:
6710963 - 财政年份:2004
- 资助金额:
$ 35.64万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别: